Pricing Log in Create free account

CG Oncology, Inc. (CGON) vs CRISPR Therapeutics AG (CRSP)

CG Oncology, Inc. and CRISPR Therapeutics AG are both Biotechnology companies. CG Oncology, Inc. is the larger, with a market value of $5.5B against $5.0B — 1.1× the size. CG Oncology, Inc. grew revenue faster over the last twelve months: 840.8% against −64.8%. CRISPR Therapeutics AG has the higher net margin (−3,368.7% vs −3,602.7%) and the higher return on invested capital (0.00% vs −4,111.6%). Across the 17 metrics below, CRISPR Therapeutics AG leads on 11 and CG Oncology, Inc. on 6.

Valuation

Metric CGON CRSP Biotechnology median
P/E n/m n/m 8.50
P/S 846.74 355.30 9.71
P/B 5.12 2.72 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 683.55 222.52 9.21
Earnings yield (4.50%) (9.66%) (33.15%)
Free cash flow yield (3.40%) (7.80%) (25.50%)

Profitability

Metric CGON CRSP Biotechnology median
Gross margin (85.20%) 100.00% 65.16%
Operating margin (4,056.18%) (3,989.99%) 0.00%
Net margin (3,602.68%) (3,368.72%) 0.00%
Free cash flow margin (2,879.62%) (2,772.74%) 0.00%
Return on equity (26.41%) (26.09%) (56.36%)
Return on assets (25.11%) (19.28%) (48.04%)
Return on invested capital (4,111.64%) 0.00% 0.00%

Growth

Metric CGON CRSP Biotechnology median
Revenue growth (TTM) 840.79% (64.80%) 6.02%
EPS growth (last fiscal year) (47.52%) (49.08%) 30.26%
Revenue growth, 5-year CAGR — 37.31% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CGON CRSP Biotechnology median
Debt to equity 0.00 0.34 0.00
Current ratio 22.22 17.85 4.72
Net debt to EBITDA 3.88 3.06 0.96

Dividend

Metric CGON CRSP Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CGON CRSP Biotechnology median
Market cap 5.48b 4.98b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack